Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13936584 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TRPM8CTSKPOLBITGA4 | |
| SCHEMBL2135267 | 0.89 | ALDH1A1 (0.51) | ALDH1A1TRPM8CTSKPOLBTACR1 | |
| SCHEMBL2135261 | 0.89 | ALDH1A1 (0.51) | ALDH1A1TRPM8CTSKPOLBTACR1 | |
| SCHEMBL2137673 | 0.89 | ALDH1A1 (0.51) | ALDH1A1TRPM8CTSKPOLBTACR1 | |
| SCHEMBL419013 | 0.87 | ATM (0.56) | ALDH1A1TRPM8POLBKMT2AL3MBTL1 | |
| SCHEMBL1508826 | 0.87 | ATM (0.56) | ALDH1A1TRPM8POLBKMT2AL3MBTL1 | |
| SCHEMBL7907847 | 0.87 | ATM (0.56) | ALDH1A1TRPM8POLBKMT2AL3MBTL1 | |
| SCHEMBL1799032 | 0.86 | ITGA4 (0.48) | ALDH1A1TRPM8POLBITGA4ITGB7 | |
| SCHEMBL4169003 | 0.86 | ITGA4 (0.60) | ALDH1A1TRPM8CTSKPOLBITGA4 | |
| SCHEMBL20394533 | 0.86 | ITGA4 (0.60) | ALDH1A1TRPM8CTSKPOLBITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | ALDH1A1 415/4885TRPM8 2266/4885CTSK 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.